Related Experiment Videos
An overview of the diagnoses in the Kabi Pharmacia International Growth Study
1Department of Clinical Research, Kabi Pharmacia Peptide Hormones, Stockholm, Sweden.
Insights
The Kabi Pharmacia International Growth Study (KIGS) analyzed 5377 children treated with growth hormone (GH). Data reveal diagnoses for idiopathic GH deficiency (GHD), GHD of known origin, and other short stature causes, aiding therapy comparisons.
Area of Science:
- Pediatric Endocrinology
- Growth Hormone Therapy
- Clinical Data Analysis
Background:
- The Kabi Pharmacia International Growth Study (KIGS) database contains comprehensive diagnostic information.
- Growth hormone deficiency (GHD) and other causes of short stature are significant pediatric concerns.
- Understanding diagnostic distributions is crucial for evaluating treatment efficacy.
Purpose of the Study:
- To provide an overview of patient diagnoses within the KIGS database.
- To analyze the etiological categories of short stature in children treated with growth hormone (GH).
- To establish a foundation for comparing modern GH therapy with historical treatments.
Main Methods:
- Retrospective analysis of patient data collected in the KIGS database up to May 1991.
- Classification of 5377 children based on their diagnosis: idiopathic GH deficiency (GHD), GHD of known origin, or other causes of short stature.
- Detailed breakdown of GHD causes, including congenital and acquired forms, and categorization of other short stature diagnoses.
Main Results:
- Idiopathic GHD accounted for 2691 children; GHD of known origin for 866; and other short stature causes for 1820.
- Congenital GHD cases (137) were often linked to central malformations (114), while acquired GHD (729) was frequently associated with tumors or leukemia (73%).
- Major 'other causes' included idiopathic short stature (635), chromosomal aberrations (337, predominantly Turner's syndrome), and intrauterine growth retardation (366).
Conclusions:
- The KIGS database provides a large-scale dataset for analyzing diverse causes of short stature in children treated with GH.
- The data facilitate comparisons between different GH therapy approaches and assessment for rarer GHD etiologies.
- This study highlights the importance of comprehensive diagnostic data for advancing pediatric growth disorder management.
Abstract:
This paper provides an overview of the diagnoses of patients entered in the Kabi Pharmacia International Growth Study (KIGS). By May 1991, data from a total of 5377 children treated with growth hormone (GH) were included in the main database. Of these children, 2691 were classified as having idiopathic GH deficiency (GHD), 866 as having GHD of known origin, and 1820 as having other causes of short stature. The majority of patients with idiopathic GHD have no history of perinatal trauma. In the patients with GHD of known origin, 137 were congenital cases and 729 acquired GHD. The largest number of congenital cases (114) belonged to the group of central malformations (e.g. septo-optic dysplasia and empty sella syndrome). Of the cases with acquired GHD, 73% were associated with tumours or leukaemia. Other causes of short stature include 12 groups of diagnoses, with more than 150 cases in four of them (idiopathic short stature, 635; defined syndromes with chromosomal aberrations, 337, of which 304 were Turner's syndrome; defined syndromes without chromosomal aberrations, 157; intrauterine growth retardation without stigmata, 366). Analysis of the KIGS data allows modern GH therapy for GHD to be compared with older treatment modalities. The study offers the advantage of larger numbers of cases than can be achieved in individual trials and allows assessment of the use of GH therapy for GHD of comparatively uncommon causes.